| Aarkstore announce a new report "Innovations | | | | oncology diagnostics market in the core areas |
| in Oncology Diagnostics: Technological advances, | | | | – diagnostic imaging, molecular diagnostics and |
| growth opportunities and future market outlook" | | | | pharmacogenetics. This includes market |
| through its vast collection of market research | | | | information and an analysis of the scientific |
| report. | | | | literature so as to identify what is really |
| Despite public policy measures to prevent cancer, | | | | innovative. |
| such as tobacco control and vaccination against | | | | •Identify what the key areas of unmet need |
| HPV, cancer is sure to remain a significant public | | | | are in the oncology diagnostics market and |
| health problem throughout the 21st century. | | | | understand which products have the greatest |
| Indeed, the global demographic shift towards an | | | | potential over the next decade. |
| ageing population and the spread of high tech | | | | •Understand what the greatest challenges are |
| modern medicine throughout the emerging | | | | for oncology diagnostics and what the best |
| economies of Asia and (maybe later) Africa, will | | | | strategies are for coping with these obstacles. |
| expand the market for cancer diagnostics globally. | | | | •Understand the competitive landscape and |
| Major developments are likely in both the IVD | | | | what companies are leading the way in terms of |
| market and in imaging-based modalities, like | | | | innovation, and what the latest partnerships |
| computed tomography, with the emphasis being | | | | regarding companion diagnostics. |
| upon the personalized medicine approach, where | | | | •Business Insights has identified five key areas |
| demand will come from physicians, patients and | | | | of innovation in the diagnostics markets, use this |
| payors – all of whom want more effective | | | | to help guide company strategy. |
| treatments and value for money. | | | | Key findings from this report |
| This report analyzes the latest innovations in | | | | Molecular diagnostics and biomarkers are the key |
| oncology diagnostics and identifies the most | | | | drivers of the oncology diagnostics market. |
| exciting new technologies and trends, ranging | | | | Despite the deep economic recession, R&D |
| from body imaging and cytology to molecular | | | | spending has held up for oncology diagnostics |
| diagnostics and pharmacogenomics. The report | | | | companies. However, M&A activity has been |
| also identifies the key challenges facing innovative | | | | impacted with the value of deals conducted in |
| diagnostics companies. | | | | 2009 far below the peak year of 2007. |
| Key Features of this report | | | | Partnerships between diagnostic firms and |
| •Analysis the latest innovations in diagnostics | | | | pharmaceutical firms represents the future of the |
| imaging in the oncology sector, covering Magnetic | | | | industry and the number of companion deals has |
| Resonance Imaging (MRI), x-ray, Computed | | | | been increasing in the past few years. |
| Tomography (CT), ultrasound, Positron Emission | | | | Virtual colonoscopy - using CT scans to build a |
| Tomography (PET), Single Photon Emission | | | | picture of the colon - is becoming an increasingly |
| Computed Tomography (SPECT) and Flow | | | | accepted alternative to invasive colonoscopy for |
| Cytometry. | | | | colorectal screening in high risk groups and the |
| •Analyzes the latest innovations in molecular | | | | general population. This presents a sizeable market |
| diagnostics and how they impact the diagnostics | | | | opportunity. |
| market. The report covers technology including | | | | Interesting research is being conducted in both |
| fluorescence in situ hybridization (FISH), | | | | ovarian cancer and for prostate cancer, which |
| polymerase chain reaction (PCR), HPV testing, | | | | could have wide-market implications. Specifically, |
| immunoassays & biomarkers, microarrays | | | | companies are looking to validate new biomarkers |
| and comparative genomic hybridization (CGH). | | | | to create more accurate tests. |
| •Analyzes the latest innovations in | | | | Key questions answered by this report |
| pharmacogenomics and covers the major | | | | What is the market potential for in vitro diagnostic |
| applications for familial cancer, breast cancer, colon | | | | products? |
| cancer and lung cancer. Also, the report provides | | | | What is the market forecast for oncology |
| an overview of the regulatory and intellectual | | | | diagnostics? |
| property environment for genetic-based tests. | | | | What are the key innovations in diagnostic testing |
| •Looks at the key commercial challenges for | | | | and diagnostic imaging? |
| innovative diagnostics companies, including the | | | | What are the major areas of unmet need in |
| impact of the recession, reimbursement, | | | | oncology diagnostics? |
| regulatory changes, pharmacoeconomics and the | | | | What are the most promising technology areas in |
| relationship between industry and academia. | | | | oncology diagnostics, and which companies are |
| The report Includes in-depth case studies on the | | | | exploiting these? |
| potential technologies available in core areas of | | | | What will be the key trends impacting the market |
| un-met need such as ovarian cancer and | | | | in the long-term? |
| colorectal cancer. | | | | How can big pharma fully exploit the opportunities |
| Key benefits of this report | | | | in the oncology diagnostics sector? |
| •Understand the latest innovations in the | | | | |